
primary studies - congress abstract

Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis and F508del/F508del-CFTR: patient-reported outcomes in a Phase 3, randomised, controlled trial (EVOLVE)

Code: CN-XXXXX013 **Year:** 2019 **Date:** 2019

Author: Sommerburg O

See also

Pneumologie (Stuttgart, Germany), 2019, 73(SUPPL. 1)

Keywords

Adult; Aged; CFTR Modulators; Genetic Predisposition to Disease; pharmacological_intervention; placebo; VX-770; VX-661; ivacaftor; Aminophenols; tezacaftor; VX-445; Symdeko; Symkevi;